Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

ABSTRACT:

SUBMITTER: Stein MN 

PROVIDER: S-EPMC5500309 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature